New cancer clinical trial: 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Published on: January 15, 2019 at 12:00PM
Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
Interventions:   Drug: Lutetium Lu 177-PSMA-617;   Biological: Pembrolizumab
Sponsors:   University of California, San Francisco;   National Cancer Institute (NCI)
Not yet recruiting
http://bit.ly/2Rzvlgz